These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 8911260

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
    Donahue PE, Smith DL, Yellin AE, Mintz SJ, Bur F, Luke DR.
    Am J Surg; 1998 Dec; 176(6A Suppl):53S-61S. PubMed ID: 9935258
    [Abstract] [Full Text] [Related]

  • 4. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F, Faulkner KL.
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [Abstract] [Full Text] [Related]

  • 5. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
    Tonelli F.
    Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
    [Abstract] [Full Text] [Related]

  • 6. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C, Belgian Multicenter Study Group.
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [Abstract] [Full Text] [Related]

  • 7. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A, Meli EZ, Mazzocchi P, Speranza V.
    Scand J Infect Dis; 1997 Jun; 29(5):503-8. PubMed ID: 9435041
    [Abstract] [Full Text] [Related]

  • 8. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ.
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [Abstract] [Full Text] [Related]

  • 9. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
    Badía X, Brosa M, Tellado JM.
    Enferm Infecc Microbiol Clin; 1999 Jul; 17 Suppl 2():86-94. PubMed ID: 10605193
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
    Walters DJ, Solomkin JS, Paladino JA.
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):551-61. PubMed ID: 10662480
    [Abstract] [Full Text] [Related]

  • 11. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E, Aseeri M, Khoshhal S.
    J Infect Public Health; 2018 Nov; 11(4):486-490. PubMed ID: 29153444
    [Abstract] [Full Text] [Related]

  • 12. Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis.
    Tally FP, Gorbach SL.
    Am J Med; 1985 Jun 07; 78(6A):145-53. PubMed ID: 3890535
    [Abstract] [Full Text] [Related]

  • 13. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.
    Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS, Pak R, Tack K.
    Ann Surg; 2001 Jan 07; 233(1):79-87. PubMed ID: 11141229
    [Abstract] [Full Text] [Related]

  • 14. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
    Maggioni P, Di Stefano F, Facchini V, Irato S, Mancuso S, Colombo M, Massobrio M, Melis GB, Crosignani P.
    J Chemother; 1998 Apr 07; 10(2):114-21. PubMed ID: 9603636
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact an anatomical site on bacteriological and clinical outcome in the management of intra-abdominal infections.
    Wilson SE, Faulkner K.
    Am Surg; 1998 May 07; 64(5):402-7. PubMed ID: 9585772
    [Abstract] [Full Text] [Related]

  • 17. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing LO, Nyström PO, Anséhn S, Bäckstrand B, Skau T.
    J Antimicrob Chemother; 1995 Jan 07; 35(1):139-48. PubMed ID: 7768761
    [Abstract] [Full Text] [Related]

  • 18. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
    Brismar B, Akerlund JE, Sjöstedt S, Johansson C, Törnqvist A, Bäckstrand B, Bång H, Andåker L, Gustafsson PO, Darle N, Angerås M, Falk A, Tunevall G, Kasholm-Tengve B, Skau T, Nyström PO, Gasslander T, Hagelbäck A, Olsson-Liljequist B, Eklund AE, Nord CE.
    Scand J Infect Dis; 1996 Jan 07; 28(5):507-12. PubMed ID: 8953683
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan.
    Takesue Y, Kusachi S, Mikamo H, Sato J, Watanabe A, Kiyota H, Iwata S, Kaku M, Hanaki H, Sumiyama Y, Kitagawa Y, Nakajima K, Ueda T, Uchino M, Mizuguchi T, Ambo Y, Konosu M, Ishibashi K, Matsuda A, Hase K, Harihara Y, Okabayashi K, Seki S, Hara T, Matsui K, Matsuo Y, Kobayashi M, Kubo S, Uchiyama K, Shimizu J, Kawabata R, Ohge H, Akagi S, Oka M, Wakatsuki T, Suzuki K, Okamoto K, Yanagihara K.
    J Infect Chemother; 2018 May 07; 24(5):330-340. PubMed ID: 29555391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.